Development of Clinically High Efficient Platforms for Individualised Treatment of Cervix Cancer

Developing Clinical High Efficiency Platforms for Individualised Treatment Through Integration of Advanced Radiation Technology, Quantitative Imaging and Molecular Biology and Machine Learning for Treatment of Cervix Cancer.

Retrospective study utilizing patient data to develop and validate Machine Learning application. Available imaging data sets of patients who have completed treatment will be used to develop Normal tissue complication probability and Tumour control probability

Hypothesis Integrating existing radiation treatment information, quantitative imaging and patient outcome data from completed and ongoing clinical trials will allow development of knowledge based systems for efficient treatment delivery and allow selection of patients for intensified treatment approaches in cervix cancer.

Study Overview

• Status: Recruiting
• Conditions: Cervix Cancer

Detailed Description

For Aim 1. Automatic delineation of complex tumour targets for cervical cancer for the Gross Tumour Volume (GTV) at baseline and at brachytherapy and High Risk Clinical Target Volume(CTV) at baseline and brachytherapy will be done on MRI.

Following structures will be processed for automation on CT

1. Low Risk Clinical Target Volume (Low Risk CTV)
2. GTV: Nodal
3. Elective Nodal Pelvic Target Volume
4. Elective Nodal Pelvic and Paraaortic Volume
5. Rectum
6. Bladder
7. Sigmoid
8. Bowel
9. Bone Marrow

For Aim 2. The Investigator intend to employ machine learning for developing more robust normal tissue toxicity prediction models. Further advanced techniques like texture analysis of radiation dose maps and follow up tissue density will also be performed to develop predictive models of toxicity. By using our patient datasets, Investigator want to create a library of proton beam plans with the proton planning systems that will be available in department of radiation oncology and using the developed normal tissue complication plots available the information of achievable doses through protons can help in identifying patients who will benefit from proton therapy.

For Aim 3. Within this project Investigator intend to integrate staging, pathology and quantitative imaging texture features for response prediction and identification of "high risk cohort" in cervix cancer. Images and clinical data from patients that have MRI at baseline will be included The texture features can be used to categorise "good" and "poor responders" after chemoradiation. For the same cohort of patients the Investigator also have tissue available including results of additional biomarkers (like AKT,LICAM, PDL1,CD4 and CD8). The Investigator intend to first correlate difference in texture features and see if there is a pattern of different molecular features. In the second step imaging and molecular features could be integrated for developing" risk prediction models". GTV and HRCTV delineated on 150 data sets at baseline and brachytherapy within Aim 1 will be utilised to categorise responders and non-responders and validate another 150 patient data sets.

• Study Type: Observational
• Enrollment (Estimated): 1800

Contacts and Locations

• Study Contact: Name: Supriya Sastri (nee Chopra), MD; Phone Number: 5113 02227405000; Email: supriyasastri@gmail.com
• Study Contact Backup: Name: Supriya Sastri (nee Chopra), MD; Phone Number: 5113 02227405000; Email: schopra@actrec.gov.in

Study Locations

• India
  • Maharashtra
    • Navi Mumbai, Maharashtra, India, 410210
      • Recruiting
      • Advanced Centre of Treatment Research and Education In Cancer,Tata Memorial Centre
      • Contact: Dr Supriya Chopra, MD; Phone Number: 5491 91-22-27405000; Email: schopra@actrec.gov.in
      • Principal Investigator: Supriya Chopra, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 90 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Cervical cancer patients treated within ongoing and completed clinical trials of chemoradiation and brachytherapy for cervix cancer at our institute with access to MRI/CT images at time of diagnosis and brachytherapy, undergoing postoperative or definitive radiotherapy and treated within trials of postoperative or definitive RT.

Description

Inclusion Criteria:

For Aim 1 and Aim 3:

• Patients treated within ongoing and completed clinical trials of chemoradiation and brachytherapy for cervix cancer with access to MRI/CT images at the time of diagnosis and brachytherapy For Aim 2
• Patients undergoing postoperative or definitive radiotherapy and treated within trials of postoperative or definitive RT.

Exclusion Criteria:

1. Lack of disease or toxicity outcomes.
2. Lack of images in the hospital database.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Generation of software for automated target delineation for cervix cancer	1. To develop and validate automated platforms for target delineation and planning for cervix cancer in time efficient manner through a. Machine learning based detection of abnormal cancerous tissues in multimodality medical diagnostic images. b . To train machine base systems for automated planning of external radiation and brachytherapy for gynaecological cancers.	3 years
Development and validation of Normal Tissue Complication Plots	2. To use existing databases and radiation dose maps, imaging texture features and adverse events data for machine learning to develop "normal tissue complication plots "and to identify cervix cancer patient subgroups that may benefit from advanced radiation techniques (like proton treatment)	3 years
Identify "high risk patient population" that may benefit from intensification of treatment in future	3. To use advanced image texture analysis within ongoing institutional and collaborative clinical trials to identify "high risk patient population" that may benefit from intensification of treatment in future	3 years

Collaborators and Investigators

• Sponsor: Tata Memorial Hospital
• Collaborators: Erasmus Medical Center; Bhabha Atomic Research Centre and Indian Institute of Technology, Mumbai.
• Investigators: Principal Investigator: Supriya Sastri (nee Chopra), MD, Tata Memorial Centre, The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)

Study record dates

Study Major Dates

• Study Start (Actual): February 24, 2022
• Primary Completion (Estimated): June 30, 2026
• Study Completion (Estimated): June 30, 2026

Study Registration Dates

• First Submitted: October 20, 2021
• First Submitted That Met QC Criteria: October 20, 2021
• First Posted (Actual): November 1, 2021

Study Record Updates

• Last Update Posted (Actual): February 20, 2026
• Last Update Submitted That Met QC Criteria: February 18, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: Machine Learning; Molecular Biology; Advanced Radiation Technology; Quantitative Imaging
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Uterine Diseases; Genital Diseases, Female; Genital Neoplasms, Female; Uterine Cervical Diseases; Uterine Neoplasms; Uterine Cervical Neoplasms
• Other Study ID Numbers: TMC IRB 900787; CTRI/2021/08/035810 (Registry Identifier: Clinical Trials Registry - India)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No